Compare Twist Bioscience Corp (TWST) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs United Airlines Holdings Inc — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while United Airlines Holdings Inc trades at $107.36 (market cap $35.13B). The key difference: United Airlines Holdings Inc is far larger — about 4.2× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals.
| TWST | UAL | |
|---|---|---|
Market Cap | $8.42B | $35.13B |
Sector | Health | Industrials |
52-Week High | $153.10 | $136.11 |
52-Week Low | $24.16 | $85.21 |
Enterprise Value | $8.35B | $52.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
United Airlines (UAL) trades at $108.24, down 2.82% today, with a bearish technical signal but strong fundamentals including a P/E of 10.13 and net income margin of 5.56%. The company has beaten EPS estimates for three consecutive quarters and announced its largest international expansion, adding 10 new routes for 2027. Cash flow trends show volatility, with 2025 net cash flow negative at -$2.86 billion but projected to turn positive in 2026.
The outlook is mixed: analyst consensus is strongly bullish with a $168.96 price target, but high jet fuel costs and geopolitical risks pose headwinds. Earnings growth and international expansion are key catalysts, while debt levels and operational efficiency remain areas to watch for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
